A 20(S)-protopanaxadiol derivative PPD12 reverses ABCB1-mediated multidrug resistance with oral bioavailability and...

Area of Science:

• Pharmacology
• Oncology
• Drug Discovery

Background:

• Multidrug resistance (MDR) mediated by ATP-binding cassette subfamily B member 1 (ABCB1) transporter significantly reduces chemotherapy efficacy and patient survival.
• Previous studies identified PPD12, a 20(S)-protopanaxadiol derivative, as a potential inhibitor of ABCB1 in cancer cells.

Purpose of the Study:

• To further evaluate the MDR reversal effects of PPD12.
• To investigate the pharmacokinetics and toxicity profile of PPD12 in vitro and in vivo.

Main Methods:

• Assessing PPD12's effect on drug resistance in KB/VCR cells over time.
• Evaluating PPD12's impact on CYP450 enzyme activities.
• Determining PPD12's oral bioavailability and tolerability in a mouse model.
• Investigating the combined toxicity of PPD12 and Adriamycin.

Main Results:

• PPD12 significantly ameliorated drug resistance in KB/VCR cells with sustained effects.
• PPD12 exhibited minimal inhibition of major CYP450 enzymes.
• PPD12 demonstrated nearly 100% oral bioavailability and was well-tolerated in mice at various doses.
• Combined administration of PPD12 and Adriamycin did not significantly increase toxicity.

Conclusions:

• PPD12 is a novel ABCB1 inhibitor with potent MDR reversal activity.
• PPD12 possesses favorable pharmacokinetic properties, including high oral bioavailability.
• PPD12 demonstrates a promising safety profile with low toxicity, both as a single agent and in combination therapy.